News | August 06, 2007

ACC/AHA Release Revised Guidelines for UA, NSTEMI Management

August 7, 2007 - The American College of Cardiology and the American Heart Association have jointly released revised Guidelines for the Management of Patients with Unstable Angina (UA)/Non-ST- Elevation Myocardial Infarction (NSTEMI). Major changes to the guidelines include: suggesting an initial non-invasive set of preliminary tests, such as a stress test, echocardiogram or radionuclide angiogram; recommending the use of anti-platelet therapy clopidogrel for at least one year after receiving a drug-eluting stent; highlighting the importance of more intense lipid and blood pressure control; and advising cessation of non-steroidal anti-inflammatory drugs (NSAIDS) use for all UA/NSTEMI patients during hospitalization.

The ability to detect and treat these conditions earlier has greatly improved over the last several years. “New evidence from pivotal trials over the past five years has been gathered together in these guidelines to give physicians up-to-date and detailed information on which treatment options will provide the best possible outcomes for their patients,” said Nanette K. Wenger, M.D., F.A.C.C., F.A.H.A., a member of the guidelines writing committee and professor of medicine in the Division of Cardiology at Emory University School of Medicine in Atlanta. “This is a major educational document for health professionals, and I trust it will become part of the core teaching for medical students, residents and graduate physicians.”

The guidelines, which were last published in 2002, have been developed for cardiovascular specialists, emergency room physicians and healthcare professionals who evaluate and treat patients with acute coronary syndrome. They focus on the diagnosis, treatment and management of patients with UA and the closely related condition of NSTEMI.

The 2002 guidelines recommended an early invasive strategy – diagnostic angiography and revascularization – as the way to treat UA/NSTEMI patients. The revised guidelines differentiate more extensively between high- and low-risk UA/NSTEMI groups, and recommend an early invasive strategy for unstable and high risk patients, with an initial conservative (non-invasive) strategy – stress test, echocardiogram or radionuclide study – as a possible treatment option in stabilized UA/NSTEMI patients and low risk patients. Risk status is determined by risk scores.

For clinical practitioners, the revised guidelines emphasize secondary prevention, recommendations that should be continued after the UA/NSTEMI patient is discharged from the hospital to reduce risk of a recurrent heart attack. “We are emphasizing the use of ACE inhibitors - drugs that protect the muscle - and prescribing aldosterone receptor blockade, a new drug category that wasn’t available previously for people with heart failure,” said Wenger. “High-dose antioxidant vitamin supplements such as beta carotene, vitamins E and C and folic acid for secondary prevention are no longer recommended because results from clinical trials have shown no benefit and possible harm.” There is also a greater emphasis on smoking cessation.

Also new in the guidelines is the call for more intense lipid and blood pressure control. More stringent LDL cholesterol-lowering therapy and blood pressure management is recommended for UA/NSTEMI patients. LDL (“bad” cholesterol) should be lower than 100 mg/dL and ideally reduced to 70 mg/dL. Blood pressure should be lower than 140/90 and for those with diabetes or chronic kidney disease, a reading lower than 130/80 is recommended.

Because platelets are thought to play a key role in recurrent heart attack, the anti-platelet therapy clopidogrel is now recommended for at least one year after placement of a drug-eluting stent and shorter term for bare metal stent and with medical therapy. “In addition we are emphasizing the value of intensive, long-term platelet therapy,” said Wenger.

Additional updates to the guidelines include recommendations to discontinue the use of hormone replacement therapy in postmenopausal women; add troponin biomarkers as markers of cardiac damage and B-type natriuretic peptide (BNP) markers as potentially useful for cardiac risk assessment; and stop the usage of non-steroidal anti-inflammatory drugs (NSAIDS) for all UA/NSTEMI patients during hospitalization.

Members of the writing committee include Jeffrey L. Anderson, M.D., Chair; Cynthia D. Adams, R.N., Ph.D.; Elliott M. Antman, M.D.; Charles R. Bridges, S.C.D., M.D.; Robert M. Califf, M.D.; Donald E. Casey, Jr, M.D., M.P.H., M.B.A.; William E. Chavey, II, M.D.; Francis M. Fesmire, M.D.; Judith S. Hochman, M.D.; Thomas N. Levin, M.D.; A. Michael Lincoff, M.D.; Eric D. Peterson, M.D., M.P.H.; Pierre Theroux, M.D.; Nanette Kass Wenger, M.D. and R. Scott Wright, M.D.

For full text: www.acc.org and AHA www.americanheart.org

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init